Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
about
FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cellsNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewMolecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaThe role of aberrant proteolysis in lymphomagenesisTax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF-κB activation.Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.GFI1 is repressed by p53 and inhibits DNA damage-induced apoptosis.RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.The mechanism of Jurkat cells apoptosis induced by Aggregatibacter actinomycetemcomitans cytolethal distending toxin.TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.Antiangiogenic effects of oridonin.Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyThe spectrum of genetic defects in chronic lymphocytic leukemia.Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesisThe p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cellsmiR-31 and miR-17-5p levels change during transformation of follicular lymphomaResults of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53.TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides.MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?Regulation of miRNA biogenesis and turnover in the immune system.TP53 mutations in human cancer: database reassessment and prospects for the next decade.Screening Feature Genes of Venous Thromboembolism with DNA Microarray.To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes.Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage.P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.The p53 Mutation/Deletion Profile in a Small Cohort of the Omani Population with Diffuse Large B-Cell Lymphoma.
P2860
Q24304887-C044D299-F593-407A-A30B-DFED52E7D8A3Q27304386-319BAB3C-B8D4-4DD5-90DE-C97C245E4943Q28074490-322387AF-C224-4F8C-9ADB-F0D506008D49Q28084404-9608F0BA-729B-4740-875F-0502F98D2D38Q30353061-A3ED053C-37C3-410A-ADB9-A2DF756B7D7DQ33755493-697D61EF-3177-480A-8EEE-FE95227B6AC2Q33846801-4622382F-79FF-4F66-995C-D323BA1DD32BQ33869257-F428D14E-8A7A-4E2E-BA19-6EF6A37DB662Q33913937-2B022F48-3ED8-4DCD-B4E3-DA42400F4BD4Q34984471-B1C84CA8-65F9-49E7-B6DD-6F5B2D7E7B92Q35187880-D865EDFC-21C0-4323-A686-C2599F825D99Q35606212-45A4809F-8A9F-4D5B-A072-B8FA7CC04ADAQ36293421-1C04BDC9-8089-45E2-9420-C4180A23F20EQ36332053-4CE54359-C7A5-46CC-9273-92FB59CC301FQ36334914-AAA3AF66-ABDE-46E4-BC11-C79EA015C2C8Q36395599-71D85FED-B74C-4644-AF59-8F6BE3A7D557Q36426587-E38DF16C-D265-4DEC-A47A-9139B634E5DCQ36494000-6A22186B-1827-45CA-AA73-E0834AF12FA6Q36509629-70E3E03F-83FD-4439-A363-C9E52924BA65Q36541067-3197C9C0-6EC5-4045-98FB-390102FC60F0Q36651351-3A1FD759-3E52-4C8A-A596-AC0D05F1577BQ36719087-63039896-B9DA-4EA9-B9C8-107D90FE21B7Q36734163-3B6C4C01-C634-4C77-B2BD-36FF1D715230Q36825602-969012E0-29A9-45FD-8580-789515E36790Q37269206-C5E740A2-2C9F-4A88-8338-B040BAEE3967Q37407941-8B5B4375-995D-44E0-8189-7D24D1DE1832Q37635027-D2BEAC8C-94E5-46CA-B738-2FF8743D53E0Q37696308-47168F3C-D380-4A74-BDE4-593EB0D64710Q38008448-4DE18077-6287-4F25-AC0A-110C46CBA906Q38088354-8E240ECD-9FF5-40AF-9374-137BFD9BE445Q38095509-0E27F3CE-A16F-4FA4-844A-756EFB6CA6C9Q38199075-6F9E0991-1F10-47CF-B1DB-9AB191E961D7Q38300411-5635C417-DC41-4681-BEAC-9712D7DCE8ACQ38536210-64469196-6086-4350-9B6C-85B70D88A096Q38882112-B2AF30E7-7058-4130-BCAA-61E3C97DF7AEQ38988248-AC72FE65-FB3F-4F45-84F4-8F69EA7ABA69Q39292664-120AC2CB-5907-4C76-B54C-BF11D8C051A1Q39406673-6F367FCA-7248-41CD-A83F-C02A562EEEA1Q41411254-66A17362-DA71-4765-8233-4F20AD27F492Q41891965-4507BC71-FEF7-48AA-B828-BA22F8369052
P2860
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
@ast
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
@en
type
label
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
@ast
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
@en
prefLabel
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
@ast
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
@en
P2093
P2860
P1433
P1476
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
@en
P2093
Carlos E Bueso-Ramos
Ken H Young
L Jeffrey Medeiros
Timothy C Greiner
Timothy J McDonnell
Zijun Y Xu-Monette
P2860
P304
P356
10.1182/BLOOD-2011-11-366062
P407
P577
2012-01-24T00:00:00Z